ABOUT US

NEWS

INVESTOR RELATIONS

简 繁 EN
Essex-Bio Group
简 繁 EN
简 繁 EN
COMPANY NEWS
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024.01.03 Download
The board of directors (the “Board”) of Essex Bio-Technology Limited (the “Company”) hereby announces that the address of head office and principal place of business in Hong Kong of the Company has been changed from “Room 2818, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong” to “Room 3206, West Tower, Shun Tak Centre, 168-200 Connaught Road, Hong Kong” with effect from 3 January 2024.
 
The telephone number, facsimile number and website of the Company remain unchanged.
 
Related news
Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China
2024-09-13
Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance
2024-08-26
Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products
2024-08-26
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024
2024-08-26
Preservative-free Unit-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
2024-08-14
EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year
2024-06-27
Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance
2024-03-19
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024-03-18
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024-01-03
Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance
2023-08-16
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-08-16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-07-26
EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”
2023-06-30
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
2023-04-14
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China
2023-04-11
Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance
2023-03-08
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-03-08
2023-02-23
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
2023-02-22
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
2023-02-10
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
2022-10-13
Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance
2022-08-24
Essex Bio-Technology Announces 2022 Interim Financial Results
2022-08-23
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”
2022-08-15
EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”
2022-07-15
Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC
2022-05-07
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting
2022-04-29
First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
2022-04-19
First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU
2022-04-08
Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million
2022-03-22
Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value
2021-12-20
First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-11-10
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-10-27
Essex Bio-Technology Reports First Half 2021 Financial Results
2021-08-12
Essex Bio-Technology Listed on Two Authoritative Lists
2021-07-25
First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-07-19
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting
2021-04-30
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-20
Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercialisation in China
2021-04-07
Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD
2021-03-19
Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half
2021-03-12
Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease
2021-02-24
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2021-01-29
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020
2020-11-23
Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases
2020-10-15
Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
2020-08-25
Essex Bio-Technology Reports First Half 2020 Financial Results
2020-08-18
Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech
2020-08-10
Essex Bio-Technology Joins X-ZELL Seed+ Investment Round
2020-04-30
FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination
2020-03-17
Preservative-free Single-dose rb-bFGF Eye Drops (Single-Dose Beifushu Eye Drops) Obtained Approval from NMPA for Commercialisation in China
2019-12-27
Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1  
2019-12-12
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
2019-08-21
Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million
2019-08-12
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-08-02
Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea
2019-07-19
Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index
2019-05-15
Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting
2019-04-29
FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively
2019-03-12
The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award
2019-01-10
Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics
2018-10-30
Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018
2018-10-29
Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China
2018-08-22
Group Turnover and Profit in the First Half of 2018 Increased 28.3%
2018-08-10
Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis
2018-07-24
Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease
2018-07-18
Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops
2018-04-12
Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA
2018-04-10
Group Profit Recorded Growth of 22.8% in 2017
2018-03-16
Change of Company Logo Represents a Transformation for Essex Bio-Technology Pioneering Global Regenerative Science & Technology
2018-03-06
Essex Bio-Technology announces investment in MeiraGTx, a biotech company developing novel gene therapy treatments
2018-02-26
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy
粤公网安备 44049102496184号粤ICP备09032349号-1
互联网药品信息服务资格证书编号:（粤）-非经营性-2024-0208 深圳网站建设 深圳联雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT